|
1
|
Jamal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer Statistics. CA Cancer J Clin. 57:43–66.
2007.
|
|
2
|
Goggins M: Identifying molecular markers
for the early detection of pancreatic neoplasia. Semin Oncol.
34:303–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Basu A and Haldar S: 2-Methoxyestradiol
mediated signaling network in pancreatic cancer. Front Biosci.
14:2170–2178. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Basu A, Castle VP, Bouziane M, Bhalla K
and Haldar S: Crosstalk between extrinsic and intrinsic cell death
pathways in pancreatic cancer: synergistic action of estrogen
metabolite and ligands of death receptor family. Cancer Res.
66:4309–4318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qanungo S, Das M, Haldar S and Basu A:
Epigallocatechin-3-gallate induces mitochondrial membrane
depolarization and caspase-dependent apoptosis in pancreatic cancer
cells. Carcinogenesis. 26:958–967. 2005. View Article : Google Scholar
|
|
6
|
Zeng Y: Principles of micro-RNA production
and maturation. Oncogene. 25:6156–6162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dalmay T and Edwards DR: MicroRNAs and the
hallmarks of cancer. Oncogene. 25:6170–6175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Negrini M, Nicoloso MS and Calin GA:
MicroRNAs and cancer – new paradigms in molecular oncology. Curr
Opin Cell Biol. 21:470–479. 2009.
|
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M,
Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and
Croce CM: miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia L, Zhang D, Du R, et al: miR15-b and
miR-16 modulate multidrug resistance by targeting BCL2 in human
gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C,
Bartucci M, Muto G, Peschle C and De Maria R: The miR-15a-miR-16-1
cluster controls prostate cancer by targeting multiple oncogenic
activities. Nat Med. 14:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression
profiles classify human cancers. Nature. 435:834–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galante JM, Mortenson MM, Bowles TL,
Virudachalam S and Bold RJ: ERK/BCL-2 pathway in the resistance of
pancreatic cancer to anoikis. J Surg Res. 152:18–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bold RJ, Virudachalam S and McConkey DJ:
BCL2 expression correlates with metastatic potential in pancreatic
cancer cell lines. Cancer. 92:1122–1129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Munshi A, Hobbs M and Meyn RE: Clonogenic
cell survival assay. Methods Mol Med. 110:21–28. 2005.
|
|
20
|
Basu A and Haldar S: Antiproliferative and
proapoptotic effects of benzyl isothiocyanate on human pancreatic
cancer cells is linked to death receptor activation and RasGAP/Rac1
down-modulation. Int J Oncol. 35:593–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roush S and Slack FJ: The let-7 family of
microRNAs. Trends Cell Biol. 18:505–516. 2008. View Article : Google Scholar
|
|
22
|
Weidhaas JB, Babar I, Nallur SM, Trang P,
Roush S, Boehm M, Gillespie E and Slack FJ: MicroRNAs as potential
agents to alter resistance to cytotoxic anticancer therapy. Cancer
Res. 67:11111–11116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar MS, Erkeland SJ, Pester RE, Chen CY,
Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung
tumor development by the let-7 microRNA family. Proc Natl Acad Sci
USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blower PE, Chung JH, Verducci JS, Lin S,
Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM,
Weinstein JN and Sadee W: MicroRNAs modulate the chemosensitivity
of tumor cells. Mol Cancer Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsang WP and Kwok TT: Epigallocatechin
gallate up-regulation of miR-16 and induction of apoptosis in human
cancer cells. J Nutr Biochem. 21:140–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scott GK, Mattie MD, Berger CE, Benz SC
and Benz CC: Rapid alteration of microRNA levels by histone
deacetylase inhibition. Cancer Res. 66:1277–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garzon R, Pichiorri F, Palumbo T,
Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder
H, Calin GA, Liu CG, Andreeff M and Croce CM: MicroRNA gene
expression during retinoic acid-induced differentiation of human
acute promyelocytic leukemia. Oncogene. 26:4148–4157. 2007.
View Article : Google Scholar : PubMed/NCBI
|
